Healthcare
Live Price
Offline$46.29
-3.88% today
1Y Change
+245.23%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
uniQure N.V. (QURE) is a Healthcare stock with a market cap of $1.18B and listed on NASDAQ. The stock last traded around $46.29 and up 245.2% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -40.6%, EPS growth of +29.7%, a dividend yield of 0.0%. What stands out right now is revenue -40.6%, EPS +29.7%, free cash flow +4.4% with operating margin -1157.9% and ROIC -24.3%. Valuation already assumes a fairly strong business story at price/sales 73.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QURE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QURE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
QURE Max Drawdown
-87.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for QURE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$524.0M
+392.1% YoY
FY Net Income
$329.6M
+360.0% YoY
Free Cash Flow
$270.5M
+266.2% YoY
Revenue Growth
-40.6%
EPS Growth
+29.7%
Gross Margin
71.1%
Net Margin
-1236.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 16M | 27M | 16M | 106M | 524M |
| Gross Profit | -347K | 9M | 2M | 103M | 499M |
| Operating Income | -185M | -184M | -283M | -143M | 311M |
| EBITDA | -179M | -161M | -253M | -108M | 319M |
| Net Income | -199M | -240M | -308M | -127M | 330M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 80M | 159M | 241M | 228M | 556M |
| Total Assets | 825M | 557M | 832M | 705M | 809M |
| Total Liabilities | 626M | 563M | 624M | 229M | 213M |
| Shareholder Equity | 199M | -7M | 208M | 476M | 596M |
| Total Debt | 537M | 66M | 138M | 143M | 136M |
| Net Debt | 456M | -93M | -103M | -85M | -421M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
288M
+298.5% YoY
Capital Expenditures
17M
+1.4% YoY
Free Cash Flow
271M
+266.2% YoY
Key ratios
Gross Margin
71.1%
Operating Margin
-1157.9%
Net Margin
-1236.0%
ROE
-174.0%
Debt / Equity
2.70x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.